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Introduction {#tca12305-sec-0005}
============

Lung cancer is the leading cause of cancer death worldwide. Non‐small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and almost half of all NSCLC patients have distant metastasis at diagnosis.[1](#tca12305-bib-0001){ref-type="ref"}, [2](#tca12305-bib-0002){ref-type="ref"} Platinum‐based doublet chemotherapy is the conventional treatment strategy for stage IV NSCLC, resulting in overall survival (OS) ranging from 8 to 11 months and progression‐free survival (PFS) of 4--6 months.[3](#tca12305-bib-0003){ref-type="ref"}, [4](#tca12305-bib-0004){ref-type="ref"} In recent years, targeted therapy has been proven to be effective in a subset of patients carrying specific genomic alterations, such as tyrosine kinase inhibitors (TKIs) in patients with epidermal growth factor receptor (EGFR) 19 or 21 exon mutations.[5](#tca12305-bib-0005){ref-type="ref"}, [6](#tca12305-bib-0006){ref-type="ref"} As a local therapy approach, thoracic radiotherapy (TRT) is typically utilized as palliative management for symptom relief or as a salvage approach for local disease progression in stage IV NSCLC.

However, randomized trials and large cohorts of retrospective studies have demonstrated that radical TRT can provide benefits with regard to both local‐regional control and OS in extended‐stage small cell lung cancer (SCLC) patients responding to systemic chemotherapy.[7](#tca12305-bib-0007){ref-type="ref"}, [8](#tca12305-bib-0008){ref-type="ref"}, [9](#tca12305-bib-0009){ref-type="ref"} In addition, a growing body of recent data have also suggested promising outcomes of TRT for selected patients with advanced NSCLC, such as oligometastases, revealing a median OS ranging from 10--27 months.[10](#tca12305-bib-0010){ref-type="ref"}, [11](#tca12305-bib-0011){ref-type="ref"}, [12](#tca12305-bib-0012){ref-type="ref"}, [13](#tca12305-bib-0013){ref-type="ref"}, [14](#tca12305-bib-0014){ref-type="ref"}, [15](#tca12305-bib-0015){ref-type="ref"}, [16](#tca12305-bib-0016){ref-type="ref"}, [17](#tca12305-bib-0017){ref-type="ref"}, [18](#tca12305-bib-0018){ref-type="ref"}, [19](#tca12305-bib-0019){ref-type="ref"}, [20](#tca12305-bib-0020){ref-type="ref"}, [21](#tca12305-bib-0021){ref-type="ref"}, [22](#tca12305-bib-0022){ref-type="ref"}, [23](#tca12305-bib-0023){ref-type="ref"}, [24](#tca12305-bib-0024){ref-type="ref"} The positive impact of aggressive local therapy has been recognized in the recent European Society for Medical Oncology guidelines, which listed the consideration of radical local RT as an option for patients with oligometastases.[4](#tca12305-bib-0004){ref-type="ref"}

Encouraging survival results of TRT in patients with extended‐stage SCLC, as well as in NSCLC patients with oligometastases, lead to the hypothesis that a subset of patients with advanced NSCLC suitable for radical local RT may include (but is not limited to) those with oligometastases; this local approach may be extrapolated to NSCLC patients with more disseminated diseases, such as those responding to systemic chemotherapy, with the expectation of improvement on local control and survival.

Herein, we retrospectively investigated the long‐term survival, survival associated factors, treatment‐related toxicities, and patterns of failure for stage IV NSCLC patients who received radical TRT, without limiting the number of metastatic foci.

Methods {#tca12305-sec-0006}
=======

Study population {#tca12305-sec-0007}
----------------

We retrospectively reviewed the individual charts of patients who were diagnosed with synchronous stage IV NSCLC and treated with TRT in our center between January 2007 and December 2011. Patients\' demographics, disease characteristics, and treatment parameters were uniformly collected. Tumor stages of all patients were double checked and reclassified using the seventh edition of the American Joint Committee on Cancer staging. TRT was considered radical if it was: (i) the primary treatment in patients who were not considered candidates for systemic therapy as a result of being medically unfit, had a low tumor burden, had metastatic lesions capable to be covered within the TRT target, or patient refusal; and (ii) consolidation management after chemotherapy halted disease progression. The biologically equivalent dose (BED10) of radiation was required to be ≥53 Gy for radical RT, which was, coincidentally, in accordance with that prescribed by recent publications of the definition of aggressive local therapy in stage IV NSCLC.[19](#tca12305-bib-0019){ref-type="ref"}, [21](#tca12305-bib-0021){ref-type="ref"} Accordingly, RT intent was considered palliative if patients required TRT as a result of post‐chemotherapy disease progression or for symptom control. In the present study, our analysis focused on patients who received radical TRT. The study was approved by the local institutional review board.

Treatment regimen {#tca12305-sec-0008}
-----------------

All patients received TRT with or without concurrent chemotherapy. As a routine, all cases were discussed at the internal chart round by all of the thoracic radiation oncologists in the department before treatment commencement. Consensus was reached that administration of TRT to these patients was reasonable and all patients in the study signed informed consent before TRT implementation. Apart from the primary tumor, the radiation target included (but was not limited to) the involved lymph node region. The use of involved lymph node region irradiation (INI) or elective node irradiation (ENI) depended on the treating physicians\' discretion. Inclusion of nearby metastatic lesions was permitted when the dose to normal tissue did not exceed the constraints. Management of metastatic lesions and the regimen of systemic therapy, such as chemotherapy or targeted therapy, were not taken into consideration in the selection of study patients.

Statistical analysis {#tca12305-sec-0009}
--------------------

Tumor response to RT was basically evaluated using Response Evaluation Criteria in Solid Tumors version 1.1.[25](#tca12305-bib-0025){ref-type="ref"} Kaplan--Meier method was used to estimate survival, while a Cox hazard regression model was rendered for univariate and multivariate analyses of survival. OS was defined as the time elapsing from the commencement of any treatment to the last follow‐up or death of any cause. PFS was defined as the duration between the commencement of any treatment and the first site of tumor progression, death of any cause, or last date of follow‐up. National Cancer Institute‐Common Terminology Criteria for Adverse Events 3.0 were adopted to evaluate treatment related toxicity. *P* \< 0.05 was considered statistically significant.

Results {#tca12305-sec-0010}
=======

Patient characteristics {#tca12305-sec-0011}
-----------------------

A total of 126 patients with stage IV NSCLC received TRT, including 81 patients with radical intent and 45 with palliative intent. If calculated from the first date of TRT administration, a significantly longer OS (16.6 vs. 9.9 months, *P* = 0.001) and PFS (4.6 vs. 3.1 months, *P* = 0.016) was observed in patients who received radical TRT. Herein, we only report detailed results of patients receiving radical TRT.

The general demographics and characteristics of study patients are shown in Table [1](#tca12305-tbl-0001){ref-type="table-wrap"}. The median age was 58 years and median BED10 to thoracic disease was 71.2 Gy. Local tumor node (TN) stage (ignoring M1 status) was I or II in 11 patients and stage III in 70 patients. Most patients experienced M1b disease. Seventy‐seven percent of patients presented with synchronous single‐organ metastasis and 52% carried \>5 metastatic foci. Half of the patients received RT or surgical resection on all metastatic lesions. Pre‐RT chemotherapy and concurrent chemotherapy were performed in 60% and 35% of study patients, respectively. The median duration between end of pre‐RT chemotherapy and TRT start was 33 days. Twenty‐five patients (adenocarcinoma : non‐adenocarcinoma = 16:9) received targeted therapies, including 23 with TKIs and two with concurrent nimotuzumab during TRT. EGFR mutation status was not available for any of the patients who received targeted therapy.

###### 

General characteristic of study patients

                                                                                                        Number of patients (%)
  ------------------------------------------------------------ ---------------------------------------- ---------------------------------------------------------
  Age                                                          Median                                   58 (36, 80)[†](#tca12305-note-0002){ref-type="fn"}
  ≤60                                                          47 (58)                                  
  \>60                                                         34 (42)                                  
  Gender                                                       Male                                     64 (79)
  Female                                                       17 (21)                                  
  Weight loss                                                  Yes                                      19 (24)
  No                                                           62 (76)                                  
  Pre‐TRT KPS                                                  ≥80                                      70 (86)
  \<80                                                         11 (14)                                  
  TN stage                                                     I‐II                                     11 (14)
  III                                                          70 (86)                                  
  M stage                                                      M1a                                      18 (22)
  M1b                                                          63 (78)                                  
  Pathology                                                    Adenocarcinoma                           39 (48)
  Non‐adenocarcinoma                                           42 (52)                                  
  Number of metastatic organ                                   Single                                   62 (77)
  Multiple                                                     19 (23)                                  
  Number of metastatic lesions                                 Single                                   25 (31)
  Non‐single                                                   56 (69)                                  
  1--5                                                         39 (48)                                  
  \>5                                                          42 (52)                                  
  Pre‐TRT chemotherapy                                         Yes                                      49 (60)
  No                                                           32 (40)                                  
  Interval between end of pre‐TRT chemotherapy and TRT start   Median                                   33 (2, 161)[†](#tca12305-note-0002){ref-type="fn"}
  Concurrent chemotherapy                                      Yes                                      28 (35)
  No                                                           53 (65)                                  
  Management of metastatic lesions                             RT all sites                             39 (48)
  RT partial sites                                             12 (15)                                  
  Surgical resection all sites                                 2 (2)                                    
  None                                                         28 (35)                                  
  BED10 (Gy)                                                   Median                                   71.2 (53.1, 132)[†](#tca12305-note-0002){ref-type="fn"}
  \<72 Gy                                                      41(51)                                   
  ≥72 Gy                                                       40 (49)                                  
  Nodal target                                                 INI                                      53 (65)
  ENI                                                          28 (35)                                  
  Targeted therapy                                             No                                       56 (69)
  Yes                                                          25 (31)                                  
                                                               Pre‐TRT                                  3 (12)[‡](#tca12305-note-0002){ref-type="fn"}
                                                               During TRT                               3 (12)[‡](#tca12305-note-0002){ref-type="fn"}
                                                               Post‐TRT                                 3 (12)[‡](#tca12305-note-0002){ref-type="fn"}
                                                               Pre‐, during and post‐TRT                2 (8)[‡](#tca12305-note-0002){ref-type="fn"}
                                                               Pre‐ and during TRT                      1 (4)[‡](#tca12305-note-0002){ref-type="fn"}
                                                               During and post‐TRT                      1 (4)[‡](#tca12305-note-0002){ref-type="fn"}
                                                               Salvage after the post‐TRT progression   12 (48)[‡](#tca12305-note-0002){ref-type="fn"}

†Range. ‡Proportion of patients who received targeted therapy. BED10, biological equivalent dose with α/β of 10; ENI, elective lymph node irradiation; INI, involved lymph node region irradiation; KPS, Karnofsky performance score; M stage, metastasis stage; TN stage, primary tumor and nodal stage; TRT, thoracic radiotherapy.
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Survival analysis {#tca12305-sec-0012}
-----------------

After radiotherapy, 80 patients were assessable for response to TRT, including partial response (PR), stable disease (SD), and progressive disease (PD) in 33 (41%), 21 (26%), and 26 (33%) patients, respectively. The median follow up time was 49.1 months and the minimum follow‐up for survivors was 31.5 months. Figure [1](#tca12305-fig-0001){ref-type="fig"} details the survival curves and corresponding 95% confidence interval (95% CI) for OS and PFS. The median OS was 20.8 months (95% CI 13.3--38.3), with actuarial one, two, three, and four‐year survival rates of 70% (95% CI 59%--79%), 42% (95% CI 31%--52%), 23% (95% CI 15%--33%), and 18% (95% CI 10%--29%), respectively. The median PFS was 8.2 months (95% CI 6.5--9.9 ), with actuarial one and two‐year PFS rates of 23% (95% CI 15%--33%) and 9% (95% CI 4%--16%), respectively.

![Survival for all patients receiving radical thoracic radiotherapy. (a) Overall survival; (b) progression free survival (solid lines represent estimated survival curves and dashed lines indicate 95% confidence intervals of survival).](TCA-7-182-g001){#tca12305-fig-0001}

Multivariate analysis of survival {#tca12305-sec-0013}
---------------------------------

Univariate analysis for OS and PFS are listed in Table [2](#tca12305-tbl-0002){ref-type="table-wrap"}. Female gender, no weight loss, post‐RT response of PR, and use of targeted therapy were factors associated with significantly longer OS, while local TN stage showed a borderline association with OS. Under multivariate analysis, post‐RT response of PR (hazard ratio \[HR\] 0.529, 95% CI 0.315--0.889, *P* = 0.016; median: 28.6 vs. 13.9 months) and use of targeted therapy (HR 0.467, 95% CI 0.267--0.817, *P* = 0.008; median: 29.5 vs. 13.8 months) remained predictive of better OS. Female gender (HR 0.531, 95% CI 0.276--1.024, *P* = 0.059; median: 28.6 vs. 15.6 months) manifested a marginal significance in predicting OS (Fig [2](#tca12305-fig-0002){ref-type="fig"}a--c).

###### 

Univariate analyses for survival endpoints

  Factor                             Overall survival   Progression‐free survival                                                                                                                                      
  ---------------------------------- ------------------ -------------------------------------------------------- -------------- -------------------------------------------------------- -------------- -------------- --
  Age                                ≤60                Ref.                                                     0.714, 1.903                                                            Ref.           0.745, 1.856   
  \>60                               1.165              0.540                                                    1.176          0.468                                                                                  
  Gender                             Male               Ref.                                                     0.263, 0.974                                                            Ref.           0.419, 1.274   
  Female                             0.506              0.041                                                    0.731          0.268                                                                                  
  Weight loss                        Yes                Ref.                                                     0.308, 0.942                                                            Ref.           0.429, 1.239   
  No                                 0.539              **0.03** [**\***](#tca12305-note-0004){ref-type="fn"}    0.729          0.243                                                                                  
  Pre‐RT KPS                         \<80               Ref.                                                     0.405, 1.527                                                            Ref.           0.447, 1.669   
  ≥80                                0.798              0.514                                                    0.872          0.687                                                                                  
  TN stage                           I‐II               Ref.                                                     0.878, 4.729                                                            Ref.           0.923, 3.736   
  III                                2.037              **0.098** [**\***](#tca12305-note-0004){ref-type="fn"}   1.857          **0.083** [**\***](#tca12305-note-0004){ref-type="fn"}                                 
  M stage                            M1a                Ref.                                                     0.518, 1.606                                                            Ref.           0.744, 2.198   
  M1b                                0.912              0.750                                                    1.279          0.374                                                                                  
  Number of metastases               1--5               Ref.                                                     0.573, 1.524                                                            Ref.           0.536, 1.325   
  \>5                                0.934              0.785                                                    0.843          0.459                                                                                  
  Single                             Ref.               0.588, 1.870                                                            Ref.                                                     0.675, 1.950                  
  Multiple                           1.048              0.873                                                    1.147          0.612                                                                                  
  Management of metastatic lesions   None               Ref.                                                     0.697, 2.044                                                            Ref.           0.703, 1.915   
  All (RT and resection)             1.194              0.518                                                    1.161          0.560                                                                                  
  Partial                            1.376              0.654, 2.894                                             0.401          1.532                                                    0.767, 3.042   0.227          
  BED 10                             \<72 Gy            Ref.                                                     0.815, 2.170                                                            Ref.           0.713, 1.768   
  ≥72 Gy                             1.330              0.254                                                    1.122          0.618                                                                                  
  Nodal target                       INI                Ref.                                                     0.550, 1.547                                                            Ref.           0.574, 1.474   
  ENI                                0.922              0.759                                                    0.920          0.728                                                                                  
  Prior chemotherapy                 Yes                Ref.                                                     0.802, 2.147                                                            Ref.           0.921, 2.314   
  No                                 1.312              0.279                                                    1.460          0.108                                                                                  
  Concurrent chemotherapy            Yes                Ref.                                                     0.557, 1.549                                                            Ref.           0.418, 1.065   
  No                                 0.929              0.779                                                    0.667          **0.090** [**\***](#tca12305-note-0004){ref-type="fn"}                                 
  Post‐RT response                   PR                 Ref.                                                     1.021, 2.840                                                            Ref.           1.389, 3.741   
  SD + PD                            1.702              **0.041** [**\***](#tca12305-note-0004){ref-type="fn"}   2.280          **0.001** [**\***](#tca12305-note-0004){ref-type="fn"}                                 
  Targeted therapy                   No                 Ref.                                                     0.272, 0.815                                                            Ref.           0.556, 1.464   
  Yes                                0.471              **0.007** [**\***](#tca12305-note-0004){ref-type="fn"}   0.902          0.677                                                                                  

\**P* value \< 0.1 as the criteria for factor selection into multivariate analyses. BED10, biological equivalent dose with α/β of 10; CI, confidence interval; ENI, elective lymph node irradiation; HR, hazard ratio; INI, involved lymph node region irradiation; KPS, Karnofsky performance score; M stage, metastasis stage; PD, progressive disease; PR, partial response; Ref., references; RT, radiotherapy; SD, stable disease; TN stage, primary tumor and nodal stage.
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![Overall survival stratified by variable factors. (a) Post‐thoracic radiotherapy response. ![](TCA-7-182-g005.jpg "image"), partial response (PR); ![](TCA-7-182-g006.jpg "image"), stable disease (SD) + progressive disease (PD). (b) Use of targeted therapy. ![](TCA-7-182-g007.jpg "image"), Yes; ![](TCA-7-182-g008.jpg "image"), No. (c) Gender. ![](TCA-7-182-g009.jpg "image"), Male; ![](TCA-7-182-g010.jpg "image"), Female. (d) Number of metastatic lesions. ![](TCA-7-182-g011.jpg "image"), 1--5 metastases; ![](TCA-7-182-g012.jpg "image"), \>5 metastases.](TCA-7-182-g002){#tca12305-fig-0002}

Univariate analyses of PFS are also shown in Table [2](#tca12305-tbl-0002){ref-type="table-wrap"}. Multivariate analysis revealed that earlier local TN stage (HR 0.347, 95%CI 0.165--0.729, *P* = 0.005; median: 11.7 vs. 7.2 months), absence of concurrent chemotherapy (HR 0.488, 95% CI 0.296--0.805, *P* = 0.005; median: 8.9 vs. 5.8 months) and post‐RT response of PR (HR 0.338, 95% CI 0.201--0.571, *P* \< 0.001; median: 10.8 vs. 6.8 months) were independent indicators for improved PFS (Fig [3](#tca12305-fig-0003){ref-type="fig"}a--c). The state of oligometastasis did not present a significant association with OS or PFS (Figs [2](#tca12305-fig-0002){ref-type="fig"}d and [3](#tca12305-fig-0003){ref-type="fig"}d).

![Progression‐free survival stratified by variable factors. (a) Post‐thoracic radiotherapy response. ![](TCA-7-182-g013.jpg "image"), PR; ![](TCA-7-182-g014.jpg "image"), SD + PD. (b) Local TN stage. ![](TCA-7-182-g015.jpg "image"), I‐II; ![](TCA-7-182-g016.jpg "image"), III. (c) Concurrent chemotherapy. ![](TCA-7-182-g017.jpg "image"), Yes; ![](TCA-7-182-g018.jpg "image"), No. (d) Number of metastatic lesions. ![](TCA-7-182-g019.jpg "image"), 1--5 metastases; ![](TCA-7-182-g020.jpg "image"), \>5 metastases.](TCA-7-182-g003){#tca12305-fig-0003}

Toxicity assessment {#tca12305-sec-0014}
-------------------

A total of 67 patients were assessable for radiation‐related lung toxicity, including 28 patients with grade 0, 33 with grade 1, three with grade 2, and three with grade 3 toxicity, resulting in 9% grade ≥2 lung toxicity. Of the 76 patients eligible for evaluation of radiation associated esophagus toxicity, 34 had grade 0, 22 had grade 1, 19 had grade 2, and one had grade 3 toxicity, introducing a grade ≥2 toxicity of 26%. No grade 4 or 5 toxicity was observed.

Patterns of failure {#tca12305-sec-0015}
-------------------

Figure [4](#tca12305-fig-0004){ref-type="fig"} depicts the patterns of failure for the study patients who experienced disease progression. Out of 81 patients, 73 developed disease progression at the last follow‐up, including 25 (34%) with local‐regional recurrence, 32 (44%) with failure at initial metastatic sites at diagnosis, and 46 (63%) with new metastases.

![Patterns of failure of the study population who experienced disease progression (*n* = 73). Circle sizes are proportional to the number of patients with corresponding progression.](TCA-7-182-g004){#tca12305-fig-0004}

Discussion {#tca12305-sec-0016}
==========

In the stage IV NSCLC cohort who received radical TRT without limiting the number of metastases, we observed promising rates of OS and PFS, along with mild RT‐related toxicities. The post‐RT tumor response of PR and use of targeted therapy were found to be associated with prolonged OS. Accordingly, earlier initial TN stage, absence of concurrent chemotherapy, and post‐RT tumor response of PR were independent predictors for better PFS. Distant failure was the dominant post‐treatment pattern of failure.

In recent years, increasing data have shown that the addition of local thoracic therapy to the systemic therapy could provide encouraging outcomes in selected patients with oligometastases, revealing a median OS ranging from 10--27 months and median PFS of 6.6--16 months (Table [3](#tca12305-tbl-0003){ref-type="table-wrap"}).[11](#tca12305-bib-0011){ref-type="ref"}, [12](#tca12305-bib-0012){ref-type="ref"}, [13](#tca12305-bib-0013){ref-type="ref"}, [14](#tca12305-bib-0014){ref-type="ref"}, [15](#tca12305-bib-0015){ref-type="ref"}, [16](#tca12305-bib-0016){ref-type="ref"}, [17](#tca12305-bib-0017){ref-type="ref"}, [18](#tca12305-bib-0018){ref-type="ref"}, [19](#tca12305-bib-0019){ref-type="ref"}, [20](#tca12305-bib-0020){ref-type="ref"}, [21](#tca12305-bib-0021){ref-type="ref"}, [22](#tca12305-bib-0022){ref-type="ref"}, [23](#tca12305-bib-0023){ref-type="ref"}, [24](#tca12305-bib-0024){ref-type="ref"} A small prospective study including 26 stage III/IV NSCLC patients with ≤3 metastatic organs (without limiting the number of metastatic lesions) also demonstrated excellent median OS of 21.8 months and median PFS of 10.2 months, as well as a tolerable toxicity profile after definitive TRT concomitant with TKIs.[26](#tca12305-bib-0026){ref-type="ref"} Based on these promising data, there is room to extrapolate local TRT to patients with \>5 metastases in the context of other potential favorable indicators, such as limited organ metastasis and response to previous chemotherapy or targeted therapy. Without limiting the number of metastatic foci, RT was considered radical if ≥53 Gy TRT was administered as first‐line or consolidation therapy in patients who did not experience disease progression after first‐line chemotherapy or targeted therapy. As expected, the subset of patients treated with radical TRT achieved significantly better OS and PFS than those who received palliative TRT, indicating that selected criteria for candidate identification for radical TRT were reasonable.

###### 

Studies of NSCLC with oligometastases treated with TRT

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year                                                                                     Trial design   Number of pts (met lesions)   Dose (Gy) (median)                                         MOS (months)   2‐year OS   3‐year OS   MPFS (months)
  ------------------------------------------------------------------------------------------------ -------------- ----------------------------- ---------------------------------------------------------- -------------- ----------- ----------- ---------------
  Iyengar, 2014[23](#tca12305-bib-0023){ref-type="ref"}, [†](#tca12305-note-0005){ref-type="fn"}   Pros           24 (52)                       27--33/3F\                                                 20.4           NA          NA          14.7
                                                                                                                                                35--40/5F\                                                                                        
                                                                                                                                                19--20/1F                                                                                         

  Collen, 2014[22](#tca12305-bib-0022){ref-type="ref"}, [‡](#tca12305-note-0005){ref-type="fn"}    Pros           26 (48)                       50/10F                                                     23             67% (1 y)   NA          11.2

  Gray, 2014[21](#tca12305-bib-0021){ref-type="ref"}, [‡](#tca12305-note-0005){ref-type="fn"}      Retro          66 (1--4)                     Resection or \>45 Gy RT                                    26.4           54%         29%         NA

  Sheu, 2014[20](#tca12305-bib-0020){ref-type="ref"}                                               Retro          69 (1--3)                     Resection or RT of 15--74 (63)                             27.1           NA          NA          11.3

  Parikh, 2014[19](#tca12305-bib-0019){ref-type="ref"}                                             Retro          53 (1--5)                     45--70 (60)                                                19             NA          NA          NA

  Su, 2013[18](#tca12305-bib-0018){ref-type="ref"}                                                 Pros           201 (312)                     30--72 (63)                                                10             16.4%       9.6%        NA

  Griffioen, 2013[17](#tca12305-bib-0017){ref-type="ref"}                                          Retro          61 (74)                       58.2 ± 9.5                                                 13.5           38%         NA          6.6

  Lopez Guerra, 2012[16](#tca12305-bib-0016){ref-type="ref"}                                       Retro          78 (103)                      45--74 (63)                                                NA             32%         25%         NA

  Hasselle, 2012[15](#tca12305-bib-0015){ref-type="ref"}                                           Retro          25 (62)                       37.6--73.9 (64.6)[§](#tca12305-note-0005){ref-type="fn"}   22.7           NA          NA          7.6

  De Ruysscher, 2012[14](#tca12305-bib-0014){ref-type="ref"}                                       Pros           39 (45)                       62.3 ± 10.1/35.9 ± 8.4 F                                   13.5           23.3%       17.5%       12.1

  Chang, 2011[13](#tca12305-bib-0013){ref-type="ref"}                                              Retro          23 (52)                       40--50/16--20F                                             Not reached    82.5%       62.5%       16

  Flannery, 2008[12](#tca12305-bib-0012){ref-type="ref"}                                           Retro          42 (42)                       45--68.4 (61.2)                                            18             34%         21% (5 y)   NA

  Khan, 2006[11](#tca12305-bib-0011){ref-type="ref"}                                               Retro          23 (26)                       60 for chemoRT 40 for pre‐OP                               20             NA          NA          12
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

†SABR to all sites of diseases. ‡Synchronous brain only oligometastases (SBO). §Median equivalent dose in 2 Gy fractions for extracranial lesions (range). chemoRT, concurrent chemoradiotherapy; met, metastasis; MOS, median overall survival; MPFS, median progression free survival; NA, not available; NSCLC, non‐small cell lung cancer; pre‐OP, prior to surgical operation; Pros, prospective; Retro, retrospective; TRT, thoracic radiotherapy.
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In the present study, in which half of the patients had more than five synchronous metastases, radical TRT led to median OS and PFS rates of 20.8 and 8.2 months, respectively. These survival data were obviously better than standard chemotherapy‐based results and seemed comparable with results from previous studies that only included patients with oligometastases.[3](#tca12305-bib-0003){ref-type="ref"}, [4](#tca12305-bib-0004){ref-type="ref"} ^,^ [11](#tca12305-bib-0011){ref-type="ref"}, [12](#tca12305-bib-0012){ref-type="ref"}, [13](#tca12305-bib-0013){ref-type="ref"}, [14](#tca12305-bib-0014){ref-type="ref"}, [15](#tca12305-bib-0015){ref-type="ref"}, [16](#tca12305-bib-0016){ref-type="ref"}, [17](#tca12305-bib-0017){ref-type="ref"}, [18](#tca12305-bib-0018){ref-type="ref"}, [19](#tca12305-bib-0019){ref-type="ref"}, [20](#tca12305-bib-0020){ref-type="ref"}, [21](#tca12305-bib-0021){ref-type="ref"}, [22](#tca12305-bib-0022){ref-type="ref"}, [23](#tca12305-bib-0023){ref-type="ref"}, [24](#tca12305-bib-0024){ref-type="ref"} Furthermore, our survival data were more encouraging than the results of the overall population in IPASS study, which resulted in median OS and PFS of 18.6 and 5.6 months, respectively, among Asian patients with stage IIIB or stage IV adenocarcinoma receiving gefitinib, accompanied by a one‐year PFS of 24%.[5](#tca12305-bib-0005){ref-type="ref"} Notably, all of the enrolled patients in the IPASS study had adenocarcinomas and almost a quarter of the patients carried stage IIIB disease, which were well accepted favorable prognostic factors for advanced NSCLC. The long‐term survivors were observed in our study population, with three and four‐year OS rates of 23% and 18%, respectively. Despite survival data, radiation‐related normal tissue toxicity should be carefully considered before making a decision to administer radical TRT. In our study, the incidences of grade ≥2 lung and esophagus toxicities were 9% and 26% respectively, justifying the safety and feasibility of TRT in this subgroup of patients.

Under multivariate analysis, post‐RT response was found to be predictive of both OS and PFS, and the earlier local TN stage was also associated with improved PFS. These factors suggest that a decrease in local tumor burden is important to eradicate residual disease after systemic treatment, prevent the spread of tumors, and further improve survival outcomes.

Another independent predictor for improved OS was the administration of targeted therapy. It could be argued that the intrinsic tumor biology advantages to TKIs in an East Asian population could have played a more important role than TRT in the promising median survival rate of 20.8 months. However, the following reasons may still support the positive role of radical TRT in this study set. First, the subgroup of patients without targeted therapy presented a median OS rate of 13.9 months (2‐year OS of 29% and 4‐year OS of 18%), which remained superior to the traditional chemotherapy‐based results. Second, the use of targeted therapy was not found to be predictive of "better‐than‐expected" PFS of 8.2 months in the present study. Third, nine out of 25 patients who received targeted therapy in our study had non‐adenocarcinoma and basically should not have responded to TKIs. Nevertheless, because of great heterogeneity in terms of the intervention timing, as well as elapsed duration of targeted therapy, a detailed analysis was inaccessible in the current study.

Interestingly, we did not find a clear survival benefit in patients with oligometastases compared with those carrying more metastatic foci. This result suggested that \>5 metastases may not be considered a strict contraindication for aggressive local therapy in patients with other favorable indicators, such as overall low tumor burden, responding to previous chemotherapy, or tolerable to aggressive doses of TRT. Unexpectedly, our study showed a detrimental impact of concurrent chemotherapy along with TRT for PFS, which is hard to explain based on available data. Prognostic factors reported in other studies including age, metastases limited to the brain, single metastasis, RT dose, or baseline performance status did not present a significant association with OS in our study.[12](#tca12305-bib-0012){ref-type="ref"}, [16](#tca12305-bib-0016){ref-type="ref"}, [17](#tca12305-bib-0017){ref-type="ref"}, [18](#tca12305-bib-0018){ref-type="ref"}, [19](#tca12305-bib-0019){ref-type="ref"} This diversity in prognostic indicators among studies may have resulted from the limitation of retrospective studies, as well as the small number of study patients.

We acknowledge the following limitations of our study. This is a chart review‐based retrospective study. The heterogeneity in patient characteristics may influence the predictive power of factors related with survival. The non‐standardized follow‐up may result in toxicity assessment unreliability. Additionally, this is a single arm study in which all analyzed patients were treated with TRT; therefore, we can only compare survival and toxicity results with historical data from previous studies, rather than straightforwardly examine the impact of TRT on survival. Further well‐designed prospective studies are warranted to assess the feasibility and efficacy of radical TRT in NSCLC with synchronous metastasis including (but not limited to) oligometastases.

Conclusions {#tca12305-sec-0017}
===========

Our results add to the growing body of evidence on the efficacy of local treatment of thoracic lesions in patients with synchronous oligometastatic NSCLC, and also provide encouraging data on the advantages of TRT in patients with a high number of metastatic lesions. Patients who achieved a post‐RT response of PR had the best outcomes. We await the results of ongoing and future prospective clinical trials in order to continue to evaluate the role of radical TRT in stage IV NSCLC patients, and to identify the subset of patients who are more likely to benefit from radical TRT.
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